{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:33Z","timestamp":1789879413558,"version":"4.0.1"},"reference-count":389,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02478","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:40:27Z","timestamp":1541983227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus"],"prefix":"10.3389","volume":"9","author":[{"given":"Maryam","family":"Dadar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minakshi","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Khandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaragurubaran","family":"Karthik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz M. N.","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanpen","family":"Chaicumpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1529-8019.2010.01350.x","article-title":"An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention","volume":"23","author":"Forcier","year":"2010","journal-title":"Dermatol Ther"},{"key":"B2","first-page":"80","article-title":"Review of HPV-related diseases and cancers","volume":"40","author":"Brianti","year":"2017","journal-title":"New Microbiologica"},{"key":"B3","volume-title":"Human Papillomavirus Infections: Epidemiology and Disease Associations","author":"Palefsky","year":"2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2051013614557476","article-title":"Human papilloma virus vaccination: impact and recommendations across the world","volume":"3","author":"Bonanni","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3329\/jemc.v6i3.29683","article-title":"Human Papilloma virus vaccine: future of cervical cancer prevention","volume":"6","author":"Fardows","year":"2016","journal-title":"J Enam Med Coll."},{"key":"B8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"Zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B9","volume-title":"ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in India","author":"Bruni","year":"2016"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev. Vaccine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/jcm4040614","article-title":"Safety and efficacy data on vaccines and immunization to human papillomavirus","volume":"4","author":"Kash","year":"2015","journal-title":"J Clin Med"},{"key":"B12","first-page":"7","article-title":"Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies","volume":"10","author":"Harper","year":"2010","journal-title":"Discov Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/14728214.2012.744393","article-title":"Emerging human papilloma virus vaccines","volume":"17","author":"Ma","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.socscimed.2016.02.006","article-title":"\u201cSaving lives\u201d: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria","volume":"153","author":"Paul","year":"2016","journal-title":"Soc Sci Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/14740338.2015.1013532","article-title":"Safety of human papillomavirus vaccines: a review","volume":"14","author":"Stillo","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.vaccine.2005.09.001","article-title":"Prophylactic HPV vaccines: reducing the burden of HPV-related diseases","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/JVI.70.2.960-965.1996","article-title":"Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus","volume":"70","author":"Christensen","year":"1996","journal-title":"J Virol"},{"key":"B18","article-title":"Human papilloma virus vaccine with disassembled and reassembled virus-like particles","author":"Volkin","year":"2001"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/21645515.2015.1103936","article-title":"HPV vaccines: translating immunogenicity into efficacy","volume":"12","author":"Turner","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.vaccine.2006.06.038","article-title":"Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.vaccine.2006.05.102","article-title":"Research needs following initial licensure of virus-like particle HPV vaccines","volume":"24","author":"Hildesheim","year":"2006","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jadohealth.2013.09.018","article-title":"Population impact of HPV vaccines: summary of early evidence","volume":"53","author":"Hariri","year":"2013","journal-title":"J Adolesc Health"},{"key":"B23","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"Morb. Mort. Wkly. Rep. Recomm. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0971-5851.96961","article-title":"Cervical cancer in India and HPV vaccination","volume":"33","author":"Kaarthigeyan","year":"2012","journal-title":"Ind J Med Paediatr Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1005587","DOI":"10.1371\/journal.ppat.1005587","article-title":"Immunizing against anogenital cancer: HPV vaccines","volume":"12","author":"Pogoda","year":"2016","journal-title":"PLoS Pathog"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1517\/13543776.2011.551114","article-title":"Advances in human papilloma virus vaccines: a review","volume":"3","author":"Tomar","year":"2014","journal-title":"Int J Basic Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0120797","DOI":"10.1371\/journal.pone.0120797","article-title":"Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles","volume":"10","author":"Kines","year":"2015","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jjco\/hyw192","article-title":"Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis","volume":"47","author":"Setiawan","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.3928\/19382359-20161216-01","article-title":"Human papillomavirus and the HPV vaccine: where are we today?","volume":"46","author":"Khan","year":"2017","journal-title":"Pediatr Ann"},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination","volume":"4","author":"Frazer","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.coi.2007.01.004","article-title":"HPV vaccines: the beginning of the end for cervical cancer","volume":"19","author":"Leggatt","year":"2007","journal-title":"Curr Opinion Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1128\/CMR.05028-11","article-title":"Epithelial cell responses to infection with human papillomavirus","volume":"25","author":"Stanley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ygyno.2010.01.024","article-title":"Pathology and epidemiology of HPV infection in females","volume":"117","author":"Stanley","year":"2010","journal-title":"Gynecol. Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpag.2011.03.001","article-title":"Human papillomavirus in infants: transmission, prevalence, and persistence","volume":"25","author":"LaCour","year":"2012","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.27713","article-title":"Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe","volume":"132","author":"Tjalma","year":"2013","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1021\/tx500034c","article-title":"Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time","volume":"27","author":"Stein","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma","volume":"29","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.28201","article-title":"Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix","volume":"134","author":"Gillison","year":"2014","journal-title":"Int J Cancer"},{"key":"B40","first-page":"258","article-title":"(CDC) Human papillomavirus-associated cancers \u2013 United States, 2004\u20132008","volume":"61","author":"Centers","year":"2012","journal-title":"MMWR Morb Mortal Wkly. Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2471\/BLT.06.038414","article-title":"Human papillomavirus and HPV vaccines: a review","volume":"85","author":"Cutts","year":"2007","journal-title":"Bull. WHO"},{"key":"B42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial","volume":"22","author":"Apter","year":"2015","journal-title":"HPV PATRICIA Study Group Clin Vaccine Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.vaccine.2014.12.019","article-title":"Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial","volume":"33","author":"Lehtinen","year":"2015","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1080\/21645515.2015.1108500","article-title":"Impact of 2, 4 and 9-valent HPV vaccines on morbidity and mortality from cervical cancer","volume":"12","author":"Luckett","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14760584.2016.1124763","article-title":"Human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases","volume":"15","author":"Skinner","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomized controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"575242","DOI":"10.1155\/2012\/575242","article-title":"Interaction between chronic inflammation and oral HPV infection in the etiology of head and neck cancers","volume":"2012","author":"Tezal","year":"2012","journal-title":"Int J Otolaryngol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s13187-017-1163-1","article-title":"Knowledge, behaviors, and attitudes about human papilloma virus among nursing students in izmir, Turkey","volume":"33","author":"Bal-Yilmaz","year":"2017","journal-title":"J. Cancer Educ."},{"key":"B51","doi-asserted-by":"publisher","first-page":"djw216","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-017-1164-0","article-title":"Effects of an education intervention about HPV self-testing for healthcare providers and staff","author":"Presser","year":"2017","journal-title":"J Cancer Educ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/vaccines2020422","article-title":"Therapeutic vaccine strategies against human papillomavirus","volume":"2","author":"Khallouf","year":"2014","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/bs.apcsb.2015.08.004","article-title":"Chapter eight-human papillomavirus vaccine: state of the art and future perspectives","volume":"101","author":"Panatto","year":"2015","journal-title":"Adv Protein Chem Struct Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1586\/14760584.2016.1157477","article-title":"Current state in the development of candidate therapeutic HPV vaccines","volume":"15","author":"Yang","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(04)17410-2","article-title":"Vaccination against human papilloma viruses shows great promise","volume":"364","author":"Lehtinen","year":"2004","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bjid.2014.02.005","article-title":"Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review","volume":"18","author":"Gon\u00e7alves","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"B58","first-page":"3663","article-title":"HPV and cervical cancer epidemiology- Current status of HPV vaccination in India","volume":"17","author":"Chatterjee","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.virusres.2016.12.002","article-title":"The current state of therapeutic and T-cell based vaccines against human papilloma viruses","volume":"231","author":"Yang","year":"2017","journal-title":"Virus Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1515\/hsz-2017-0105","article-title":"Human papilloma virus first and second generation vaccines- current status and future directions","volume":"398","author":"Pouyanfard","year":"2017","journal-title":"Biol Chem"},{"key":"B61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein\u2013based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol Immunother."},{"key":"B62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.aids.0000226955.02719.26","article-title":"A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals","volume":"20","author":"Palefsky","year":"2006","journal-title":"AIDS"},{"key":"B63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","article-title":"A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia","volume":"106","author":"Roman","year":"2007","journal-title":"Gynecol Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"Einstein","year":"2007","journal-title":"Gynecol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/TCRM.S81825","article-title":"Recurrent respiratory papillomatosis: current and future perspectives","volume":"11","author":"Carifi","year":"2015","journal-title":"Ther. Clin. RiskManag."},{"key":"B66","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1874357901206010264","article-title":"Therapeutic human papillomavirus (HPV) vaccines: a novel approach","volume":"6","author":"Kawana","year":"2012","journal-title":"Open Virol J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1158\/1538-7445.AM2015-2507","article-title":"Bivalent adenylate cyclase (CYA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time","volume":"75","author":"Esquerr\u00e9","year":"2015","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.4161\/hv.23373","article-title":"Two therapeutic HPV vaccine candidates successful in phase 1","volume":"8","author":"Riedmann","year":"2012","journal-title":"Hum Vaccin Immunother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/156802612802652402","article-title":"Advances in peptide-based human papillomavirus therapeutic vaccines","volume":"12","author":"Liu","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-012-1292-7","article-title":"A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions","volume":"61","author":"de Vos van Steenwijk","year":"2012","journal-title":"Cancer Immunol Immunotherapy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N.Engl.J. Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J. Transl.Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"292951","DOI":"10.5402\/2011\/292951","article-title":"Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial","volume":"2011","author":"Solares","year":"2011","journal-title":"ISRN Obstet. Gynecol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jtbi.2014.01.018","article-title":"A novel multi-epitope peptide vaccine against cancer: an in silico approach","volume":"349","author":"Nezafat","year":"2014","journal-title":"J Theor Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00262-012-1259-8","article-title":"TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers","volume":"61","author":"Barrios","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jbi.2014.11.003","article-title":"An overview of bioinformatics tools for epitope prediction: implications on vaccine development","volume":"53","author":"Soria-Guerra","year":"2015","journal-title":"J Biomed Inform"},{"key":"B77","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/bib\/bbw025","article-title":"Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics","volume":"18","author":"Dhanda","year":"2016","journal-title":"Brief Bioinform"},{"key":"B78","first-page":"1","article-title":"Vaccine development using recombinant DNA technology","volume":"38","author":"Jackwood","year":"2008","journal-title":"Council Agric Sci Technol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13073-015-0245-0","article-title":"Immunoinformatics and epitope prediction in the age of genomic medicine","volume":"7","author":"Backert","year":"2015","journal-title":"Genome Med"},{"key":"B80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-62703-342-8_8","article-title":"Databases and in silico tools for vaccine design","volume-title":"In Silico Models for Drug Discovery. Methods in Molecular Biology (Methods and Protocols), Vol. 993","author":"He","year":"2013"},{"key":"B81","doi-asserted-by":"publisher","first-page":"15751","DOI":"10.1038\/srep15751","article-title":"Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: in-silico and in-vivo insight to vaccine development","volume":"5","author":"Kumar","year":"2015","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.13040\/IJPSR.0975-8232.4(10).4758-62","article-title":"In silico vaccine design against the target L1 binding protein of human papillomavirus, an etiological agent of cervical cancer, using bioinformatics tools","volume":"42","author":"Kaushik","year":"2013","journal-title":"Int J Pharm Sci Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.vaccine.2013.02.065","article-title":"HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach","volume":"31","author":"Yao","year":"2013","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e0138686","DOI":"10.1371\/journal.pone.0138686","article-title":"Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine","volume":"10","author":"de Oliveira","year":"2015","journal-title":"PLoS ONE"},{"key":"B85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fimmu.2011.00075","volume":"13","author":"Keskin","year":"2011","journal-title":"Front Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.6026\/97320630013086","article-title":"Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18","volume":"13","author":"Baidya","year":"2017","journal-title":"Bioinformation"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1128\/JVI.80.6.2621-2630.2006","article-title":"Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1","volume":"80","author":"Kuck","year":"2006","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vector vaccines against infectious diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2011.202","article-title":"Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques","volume":"23","author":"Nieto","year":"2012","journal-title":"Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/cgt.2012.55","article-title":"A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors","volume":"19","author":"Wieking","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","article-title":"Attenuated measles virus as a vaccine vector","volume":"25","author":"Zuniga","year":"2007","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2009.01.061","article-title":"Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma","volume":"27","author":"Cantarella","year":"2009","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1016\/j.vaccine.2016.07.051","article-title":"Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine","volume":"34","author":"Gupta","year":"2016","journal-title":"Vaccine"},{"key":"B94","article-title":"Combined measles-human papilloma vaccine","author":"Mendiretta","year":"2017"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1650::AID-CNCR20>3.0.CO;2-L","article-title":"Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus","volume":"88","author":"Graham","year":"2000","journal-title":"Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garcia-Hernandez","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"B97","first-page":"585","article-title":"Preventive and therapeutic vaccines against human papillomaviruses associated cervical cancers","volume":"15","author":"Nayereh","year":"2012","journal-title":"Iran J Basic Med Sci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/10430340460745757","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gene Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00063030-200721010-00006","article-title":"MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I\/II study","volume":"21","author":"Albarran","year":"2007","journal-title":"Bio. Drugs"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00488-6","article-title":"Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer","volume":"19","author":"Adams","year":"2001","journal-title":"Vaccine"},{"key":"B101","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B102","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunization in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","author":"Davidson","year":"2004","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s002620000125","article-title":"A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity","volume":"49","author":"Rosales","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"HumGene Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"169e161","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstetr Gynecol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"B108","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.4049\/jimmunol.167.11.6471","article-title":"Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16","volume":"167","author":"Gunn","year":"2001","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.4161\/hv.34378","article-title":"ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen","volume":"10","author":"Cory","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1128\/JVI.78.16.8468-8476.2004","volume":"78","author":"Peng","year":"2004","journal-title":"J Virol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"721","DOI":"10.21037\/jgo.2016.08.03","article-title":"Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach","volume":"7","author":"Morris","year":"2016","journal-title":"J Gastrointest Cancer."},{"key":"B112","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.virusres.2005.02.001","article-title":"A human papillomavirus type 16 vaccine by oral delivery of L1 protein","volume":"110","author":"Sasagawa","year":"2005","journal-title":"Virus Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci. USA"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00705-009-0484-8","article-title":"Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris","volume":"154","author":"Bazan","year":"2009","journal-title":"Arch Virol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1586\/erv.12.151","article-title":"Virus-like particles for the prevention of human papillomavirus-associated malignancies","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccine"},{"key":"B118","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV \u2013 immune response to infection and vaccination","volume":"5","author":"Stanley","year":"2010","journal-title":"Infect Agent Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.vaccine.2013.10.081","article-title":"HPV vaccines to prevent cervical cancer and genital warts: an update","volume":"32","author":"Dochez","year":"2014","journal-title":"Vaccine"},{"key":"B120","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/GRF.0000000000000027","article-title":"Primary strategies for HPV infection and cervical cancer prevention","volume":"57","author":"Harper","year":"2014","journal-title":"Clin Obstet Gynecol"},{"key":"B121","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B123","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/CVI.00164-07","article-title":"Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever","volume":"14","author":"Fraillery","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/abbs\/gmn016","article-title":"Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model","volume":"41","author":"Li","year":"2009","journal-title":"Acta Biochim Biophys Sin."},{"key":"B127","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.4161\/hv.36084","article-title":"HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model","volume":"10","author":"Yan","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-2-167","article-title":"Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium","volume":"2","author":"Cortes-Perez","year":"2009","journal-title":"BMC Res Notes"},{"key":"B129","first-page":"891","article-title":"Human papillomavirus type16-L1 VLP production in insect cells","volume":"16","author":"Abdoli","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.virol.2009.04.004","article-title":"Enhanced papillomavirus-like particle production in insect cells","volume":"388","author":"Senger","year":"2009","journal-title":"Virology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1006\/viro.1995.1283","article-title":"Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae","volume":"209","author":"Hofmann","year":"1995","journal-title":"Virology"},{"key":"B132","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/JVI.72.7.6151-6154.1998","article-title":"Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies","volume":"72","author":"Rose","year":"1998","journal-title":"J Virol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila.)"},{"key":"B134","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein (Sau Paulo)"},{"key":"B135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/prep.1999.1155","article-title":"Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae","volume":"17","author":"Cook","year":"1999","journal-title":"Protein Expr Purif"},{"key":"B136","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12275-012-2292-1","article-title":"The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae","volume":"50","author":"Kwag","year":"2012","journal-title":"J Microbiol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4161\/hv.26846","article-title":"Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial","volume":"10","author":"Hu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.antiviral.2013.12.003","article-title":"Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine","volume":"102","author":"Xu","year":"2014","journal-title":"Antivir Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1099\/jmm.0.47073-0","article-title":"Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1\/L2 virus-like particles","volume":"56","author":"Xu","year":"2007","journal-title":"J Med. Microbiol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/pbi.12089","article-title":"Immunogenic assessment of plant-produced human papillomavirus type 16 L1\/L2 chimaeras","volume":"11","author":"Pineo","year":"2013","journal-title":"Plant Biotechnol J"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.vaccine.2013.07.052","article-title":"A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants","volume":"31","author":"Tumban","year":"2013","journal-title":"Vaccine"},{"key":"B142","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/14760584.2016.1157479","article-title":"Progress and prospects for L2-based human papillomavirus vaccines","volume":"15","author":"Jiang","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"B143","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1586\/14760584.2014.865523","article-title":"Second-generation prophylactic HPV vaccines: successes and challenges","volume":"13","author":"Tyler","year":"2014","journal-title":"Expert Rev Vaccine"},{"key":"B144","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1128\/JVI.00449-16","article-title":"Broad cross protection is induced by a human papillomavirus vaccine composed of L1\/L2 chimeric virus-like particles in preclinical models","volume":"90","author":"Boxus","year":"2016","journal-title":"J Virol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1128\/JVI.02588-08","article-title":"Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity","volume":"83","author":"Sch\u00e4dlich","year":"2009","journal-title":"J Virol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.4161\/21645515.2014.970973","article-title":"Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine","volume":"10","author":"Hassan","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B147","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papilloma virus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4161\/hv.34303","article-title":"Anti-tumor effects of genetic vaccines against HPV major oncogenes","volume":"11","author":"Cordeiro","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising expectations for subunit vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J Infect Dis"},{"key":"B150","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev.immunol.15.1.617","article-title":"DNA vaccines","volume":"15","author":"Donnelly","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11259-008-9040-3","article-title":"DNA vaccines and their applications in veterinary practice: Current perspectives","volume":"32","author":"Dhama","year":"2008","journal-title":"Vet Res Commun"},{"key":"B153","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/emm.2007.74","article-title":"DNA vaccines for cervical cancer: from bench to bed side","volume":"39","author":"Hung","year":"2007","journal-title":"Exp Mol Med"},{"key":"B154","first-page":"622","article-title":"Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia","volume":"10","author":"Alvarez-Salas","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"B155","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(09)70227-X","article-title":"Development of therapeutic HPV vaccines","volume":"10","author":"Trimble","year":"2009","journal-title":"Lancet Oncol"},{"key":"B156","first-page":"18","article-title":"Further stimulation of cellular immune responses through association of HPV-16 E6, E7 and L1 genes in order to produce more effective therapeutic DNA vaccines in cervical cancer model","volume":"8","author":"Fazeli","year":"2015","journal-title":"Iran J Cancer Prev"},{"key":"B157","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jviromet.2014.05.013","article-title":"DNA vaccine encoding HPV-16 E7 with mutation in LYCYE pRb-binding motif induces potent anti-tumor responses in mice","volume":"206","author":"Bahrami","year":"2014","journal-title":"J Virol Methods"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/mt.2015.120","article-title":"Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity","volume":"23","author":"Villarreal","year":"2015","journal-title":"Mol Ther"},{"key":"B159","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/1078-0432.CCR-16-0085","article-title":"GTL001, A therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: results of a phase I clinical trial","volume":"22","author":"Van Damme","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3892\/or.2013.2742","article-title":"HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine","volume":"30","author":"Zong","year":"2013","journal-title":"Oncol Rep"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e1026531","DOI":"10.1080\/2162402X.2015.1026531","article-title":"Trial watch: naked and vectored DNA-based anticancer vaccines","volume":"4","author":"Bloy","year":"2015","journal-title":"Oncoimmunology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"155ra138","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e23803","DOI":"10.4161\/onci.23803","article-title":"Trial watch: DNA vaccines for cancer therapy","volume":"2","author":"Senovilla","year":"2013","journal-title":"Oncoimmunology"},{"key":"B165","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1574891X113089990037","article-title":"Recent advances in design of immunogenic and effective naked DNA vaccines against cancer","volume":"9","author":"Fioretti","year":"2014","journal-title":"Recent Pat. Anticancer Drug Discov"},{"key":"B166","doi-asserted-by":"publisher","first-page":"e28185","DOI":"10.4161\/onci.28185","article-title":"Trial watch: DNA vaccines for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"key":"B167","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.urolonc.2013.09.014","article-title":"Preclinical and clinical development of DNA vaccines for prostate cancer","volume":"34","author":"Colluru","year":"2016","journal-title":"Urol Oncol"},{"key":"B168","first-page":"1","article-title":"Plant based oral vaccines for human and animal pathogens \u2013 a new era of prophylaxis: current and future perspectives","volume":"1","author":"Dhama","year":"2013","journal-title":"J Exp Biol Agri Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/mab.2014.0049","article-title":"Expression of recombinant vaccines and antibodies in plants","volume":"33","author":"Ko","year":"2014","journal-title":"Monoclon Antib Immunodiag Immunother"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70781-1","article-title":"Red-algae derivative could be useful adjunct to HPV vaccine","author":"Bagchi","year":"2006","journal-title":"Lancet Oncol:"},{"key":"B171","doi-asserted-by":"publisher","first-page":"e61473","DOI":"10.1371\/journal.pone.0061473","article-title":"A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection","volume":"8","author":"Demurtas","year":"2013","journal-title":"PLoS ONE"},{"key":"B172","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/abbs\/37.3.153","article-title":"Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants","volume":"37","author":"Liu","year":"2005","journal-title":"Acta Biochim Biophys Sin"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00705-003-0119-4","article-title":"Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv","volume":"148","author":"Varsani","year":"2003","journal-title":"Arch Virol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1472-6750-7-56","article-title":"Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum","volume":"7","author":"Kohl","year":"2007","journal-title":"BMC Biotechnol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12038-011-9177-z","article-title":"Transient expression of Human papillomavirus type 16 L2 epitope fused to N-and C-terminus of coat protein of Potato virus X in plants","volume":"37","author":"Cerovska","year":"2012","journal-title":"J Biosci"},{"key":"B176","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1467-7652.2008.00338.x","article-title":"Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic","volume":"6","author":"Mill\u00e1n","year":"2008","journal-title":"Plant Biotechnol J"},{"key":"B177","doi-asserted-by":"publisher","first-page":"20431","DOI":"10.1038\/srep20431","article-title":"Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells","volume":"6","author":"Lamprecht","year":"2016","journal-title":"Sci Rep"},{"key":"B178","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1016\/j.vaccine.2009.01.068","article-title":"An E7-based therapeutic vaccine protects mice against HPV16 associated cancer","volume":"27","author":"Venuti","year":"2009","journal-title":"Vaccine"},{"key":"B179","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1467-7652.2011.00612.x","article-title":"Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes","volume":"9","author":"Waheed","year":"2011","journal-title":"Plant Biotechnol J"},{"key":"B180","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12985-014-0205-0","article-title":"Plant-based vaccine against viruses","volume":"11","author":"Rybicki","year":"2014","journal-title":"Virol. J"},{"key":"B181","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12967-014-0353-4","article-title":"Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer","volume":"12","author":"Rahma","year":"2014","journal-title":"J Transl Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.7314\/APJCP.2015.16.9.3843","article-title":"Immunotherapeutic effects of dendritic cells pulsed with a codon-optimized HPV 16 E6 and E7 fusion gene in vivo and in vitro","volume":"16","author":"Zhou","year":"2014","journal-title":"Asian Pac. J Cancer Prev."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3892\/ijo.2013.2027","article-title":"Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus","volume":"43","author":"Zhu","year":"2013","journal-title":"Int J Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.7314\/APJCP.2014.15.14.5909","article-title":"Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer\u2013a feasibility study","volume":"15","author":"Ramanathan","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B186","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1200\/JCO.2014.56.8733","article-title":"Evidence-based therapy for recurrent cervical cancer","volume":"32","author":"Monk","year":"2014","journal-title":"J Clin Oncol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1200\/JCO.2014.59.0331","article-title":"There are two prophylactic human papillomavirus vaccines against cancer, and they are different","volume":"33","author":"Tjalma","year":"2015","journal-title":"J Clin Oncol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1517\/14740338.2015.1073710","article-title":"The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases","volume":"14","author":"Baker","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1080\/21645515.2016.1143159","article-title":"Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom","volume":"12","author":"Brown","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1080\/21645515.2016.1147634","article-title":"Morbidity and mortality of vulvar and vaginal cancers: impact of 2-, 4-, and 9-valent HPV vaccines","volume":"12","author":"Buchanan","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B193","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicenter phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial","volume":"341","author":"Future","year":"2010","journal-title":"BMJ"},{"key":"B195","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nyg\u00e5rd","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B196","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"B197","first-page":"107","article-title":"Cervarix\u2122: a vaccine for the prevention of HPV 16, 18-associated cervical cancer","volume":"2","author":"Monie","year":"2008","journal-title":"Biol Targets Ther"},{"key":"B198","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine."},{"key":"B199","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"key":"B200","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/jcmm.12284","article-title":"HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumor cells","volume":"18","author":"Van den Bergh","year":"2014","journal-title":"J Cell Mol Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"B203","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"B204","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/ 18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"B205","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B206","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/1471-0528.13070","article-title":"Persistence of immune responses to the HPV-16\/18 AS04-adjuvanted vaccine in women aged 15\u201355 years and first-time modelling of antibody responses in mature women: results from an open-label 6\u2013year follow-up study","volume":"122","author":"Schwarz","year":"2015","journal-title":"BJOG"},{"key":"B207","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/21645515.2015.1054584","article-title":"Projected impact of Cervarix\u2122 vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom","volume":"12","author":"Effelterre","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B208","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B209","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"De Vincenzo","year":"2014","journal-title":"Int J Womens Health"},{"key":"B210","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cct.2016.10.006","article-title":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","volume":"52","author":"Luxembourg","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"B211","doi-asserted-by":"publisher","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics."},{"key":"B212","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40136-016-0119-z","article-title":"HPV vaccines for treatment and prevention of recurrent respiratory papillomatosis","volume":"4","author":"Santarelli","year":"2016","journal-title":"Curr Otorhinolaryngol Rep"},{"key":"B213","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","article-title":"An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany","volume":"17","author":"Largeron","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B214","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2016.03.016","article-title":"Gardasil-9: A global survey of projected efficacy","volume":"130","author":"Zhai","year":"2016","journal-title":"Antivir Res."},{"key":"B215","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s40267-016-0337-y","article-title":"9-Valent human papillomavirus recombinant vaccine (Gardasil\u00ae 9): a guide to its use in the EU","volume":"32","author":"McKeage","year":"2016","journal-title":"Drugs Ther Perspect"},{"key":"B216","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40273-016-0407-y","article-title":"Cost effectiveness of HPV vaccination: asystematic review of modelling approaches","volume":"34","author":"Pink","year":"2016","journal-title":"Pharmaco Economics"},{"key":"B217","doi-asserted-by":"publisher","first-page":"e0174038","DOI":"10.1371\/journal.pone.0174038","article-title":"GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression","volume":"12","author":"Esquerr\u00e9","year":"2017","journal-title":"PLoS ONE"},{"key":"B218","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/0008-5472.641.65.2","article-title":"Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein","volume":"65","author":"Preville","year":"2005","journal-title":"Cancer Res"},{"key":"B219","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1158\/0008-5472.CAN-07-0321","article-title":"Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system","volume":"67","author":"Berraondo","year":"2007","journal-title":"Cancer Res"},{"key":"B220","first-page":"399","article-title":"Update of the new 9-valent vaccine for human papilloma virus prevention","volume":"62","author":"Yang","year":"2016","journal-title":"Can Fam Physician"},{"key":"B221","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"key":"B222","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/INF.0000000000000773","volume":"34","author":"Vesikari","year":"2015","journal-title":"J"},{"key":"B223","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu","year":"2015","journal-title":"Vaccine"},{"key":"B224","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1016\/j.vaccine.2011.04.050","article-title":"Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16\/18 vaccine in Netherlands","volume":"29","author":"van'tKlooster","year":"2011","journal-title":"Vaccine"},{"key":"B225","doi-asserted-by":"publisher","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term foll ow-up observation of the safety, immunogenicity, and effectiveness of GardasilTM in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS ONE"},{"key":"B226","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of 1 9-valent HV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"30","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"B227","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years(-the MAM study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.vaccine.2016.02.040","article-title":"Adverse events following HPV vaccination, Alberta 2006-2014","volume":"34","author":"Liu","year":"2016","journal-title":"Vaccine"},{"key":"B229","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase-III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"key":"B230","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1080\/21645515.2016.1160178","article-title":"Is HPV vaccination in pregnancy safe?","volume":"12","author":"Bonde","year":"2016","journal-title":"Hum Vacc Immunotherapeut."},{"key":"B231","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papillomavirus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun"},{"key":"B232","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Huamn papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"B233","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2018.04.007","article-title":"Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis","volume":"132","author":"Mouchet","year":"2018","journal-title":"Pharmacol Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pvr.2017.12.004","article-title":"Efficacy, immunogenicity and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women","volume":"5","author":"Ruiz-Sternberg","year":"2018","journal-title":"Papillomavirus Res"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barre syndrome after human papillomavirus vaccine: a sefl-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s00415-008-0867-x","article-title":"HPV vaccine: a cornerstone of female health \u2013 a possible cause of ADEM?","volume":"255","author":"Sch\u00e4ffer","year":"2008","journal-title":"J Neurol"},{"key":"B237","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"Clouston P, Barnett MH","volume":"15","author":"Sutton","year":"2009","journal-title":"Sclerosis"},{"key":"B238","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/0883073809349322","article-title":"A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus","volume":"25","author":"Dimario","year":"2010","journal-title":"J Child Neurol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndrome","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B240","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.2169\/internalmedicine.55.5472","article-title":"Two cases of acute disseminated encephalomyelitis following vaccination against human papilloma virus","volume":"55","author":"Sekiguchi","year":"2016","journal-title":"Intern Med"},{"key":"B241","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.clineuro.2016.03.023","article-title":"Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations","volume":"144","author":"Chang","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B242","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12026-016-8815-9","article-title":"Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database","volume":"65","author":"Geier","year":"2017","journal-title":"Immunol Rev"},{"key":"B243","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/CJI.0b013e318248f17f","article-title":"Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine","volume":"35","author":"Melief","year":"2012","journal-title":"J Immunother."},{"key":"B244","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ygyno.2013.08.025","article-title":"Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape","volume":"131","author":"Conesa-Zamora","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"24995","DOI":"10.1074\/jbc.270.42.24995","article-title":"Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)","volume":"270","author":"Singh","year":"1995","journal-title":"J Biol Chem"},{"key":"B246","first-page":"363","article-title":"Anticancer potential of curcumin: preclinical and clinical studies","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Anticancer Res"},{"key":"B247","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/mc.20170","article-title":"Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NF-\u03baB and AP-1 translocation, and modulation of apoptosis","volume":"45","author":"Divya","year":"2006","journal-title":"Mol Carcinog"},{"key":"B248","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3332\/ecancer.2015.525","article-title":"Curcumin modulates cellular AP-1, NF-\u03baB, and HPV16 E6 proteins in oral cancer","volume":"9","author":"Mishra","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B249","doi-asserted-by":"publisher","first-page":"13375","DOI":"10.18632\/oncotarget.14533","article-title":"Identification and characterization of HPV-independent cervical cancers","volume":"8","author":"Banister","year":"2017","journal-title":"Oncotarget"},{"key":"B250","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00262-008-0596-0","article-title":"Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts","volume":"58","author":"Tseng","year":"2009","journal-title":"Cancer Immunol Immunother."},{"key":"B251","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.02.020","article-title":"CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy","volume":"136","author":"Cao","year":"2010","journal-title":"Clin Immunol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2011.116","article-title":"Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know","volume":"8","author":"Rosenberg","year":"2011","journal-title":"Nat Rev Clin Oncol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/1078-0432.CCR-05-1178","article-title":"Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine","volume":"12","author":"Haas","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B254","doi-asserted-by":"publisher","first-page":"10247","DOI":"10.1158\/0008-5472.CAN-08-1494","article-title":"Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res"},{"key":"B255","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc1894","article-title":"Photodynamic therapy and anti-tumour immunity","volume":"6","author":"Castano","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B256","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1039\/c0pp00354a","article-title":"Photodynamic therapy enhancement of anti-tumor immunity","volume":"10","author":"Brackett","year":"2011","journal-title":"Photochem Photobiol Sci."},{"key":"B257","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1039\/c0pp00343c","article-title":"Cancer vaccines generated by photodynamic therapy","volume":"10","author":"Korbelik","year":"2011","journal-title":"Photochem Photobiol Sci"},{"key":"B258","doi-asserted-by":"publisher","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of human papillomavirus-related disease","volume":"30","author":"Stern","year":"2012","journal-title":"Vaccine"},{"key":"B259","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pdpdt.2015.12.004","article-title":"Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection","volume":"13","author":"Fu","year":"2016","journal-title":"Photodiag Photodyn Ther"},{"key":"B260","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1751-1097.2011.01060.x","article-title":"Treatment of HPV infection-associated cervical condylomata acuminata with 5-aminolevulinic acid-mediated photodynamic therapy","volume":"88","author":"Wang","year":"2012","journal-title":"Photochem Photobiol"},{"key":"B261","doi-asserted-by":"crossref","first-page":"206.8","DOI":"10.4049\/jimmunol.192.Supp.206.8","article-title":"HPV based photodynamic therapy: a new approach for anti-cancer therapy (VAC12P","volume":"192","author":"Kines","year":"2014","journal-title":"J Immunol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/lsm.22041","article-title":"Photodynamic therapy for cervical intraepithelial neoplasia 1-3 and human papillomavirus (HPV) infection with methylaminolevulinate and hexaminolevulinate \u2013 adouble-blind, dose-finding study","volume":"44","author":"Soergel","year":"2012","journal-title":"Lasers Surg Med"},{"key":"B263","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/13543784.2015.990150","article-title":"Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia","volume":"24","author":"Hillemanns","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B264","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/lary.20709","article-title":"Photodynamic therapy of cottontail rabbit papillomavirus-induced papillomas in a severe combined immunodeficient mouse xenograft system","volume":"120","author":"Lee","year":"2010","journal-title":"Laryngoscope"},{"key":"B265","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4172\/2161-0703.1000158","article-title":"Antimicrobial photodynamic therapy: anew therapeutic option to combat infections","volume":"3","author":"Rosa","year":"2014","journal-title":"J Med Microb Diagn"},{"key":"B266","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijgo.2012.10.014","article-title":"Meta-analysis of the effectiveness of cryotehrapy in the treatment of cervical intraepithelial neoplasia","volume":"120","author":"Sauvaget","year":"2013","journal-title":"Int J Gynaecol Obstet"},{"key":"B267","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bpobgyn.2011.11.004","article-title":"Alternative approaches to cervical cancer screening for developing countries","volume":"26","author":"Wright","year":"2012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B268","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.conctc.2017.09.008","article-title":"Efficacy of antiviral drug AV2 in the treatment of human papilloma virus\u2013associated precancerous lesions of the uterine cervix: arandomized placebo-controlled clinical trial in Kinshasa, DR Congo","volume":"8","author":"Mutombo","year":"2017","journal-title":"(KINVAV study) Contemp Clin Trials Commun"},{"key":"B269","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/LGT.0000000000000131","article-title":"The effect of cryotherapy on human papilloma virus clearance among HIV-positive women in Lusaka, Zambia","volume":"19","author":"Katundu","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"B270","first-page":"120","article-title":"Antivirals","volume-title":"Human Papillomaviruses. Clinical and Scientific Advances","author":"Greenfield","year":"2001"},{"key":"B271","first-page":"205","article-title":"Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions","volume":"78","author":"Krebs","year":"1991","journal-title":"Obstet Gynecol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0304-3835(02)00039-3","article-title":"Down-regulation of human papillomavirus E6\/E7 oncogene by arsenic trioxide in cervical carcinoma cells","volume":"181","author":"Um","year":"2002","journal-title":"Cancer Lett"},{"key":"B273","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bbrc.2004.04.037","article-title":"Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factorkappaB in human HPV-18 E6-positive HEp-2 cells","volume":"318","author":"Singh","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B274","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tjog.2013.10.004","article-title":"Efficacy of imiquimod 5% cream for persistent human papillomavirus in genital intraepithelial neoplasm","volume":"52","author":"Chen","year":"2013","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B275","doi-asserted-by":"publisher","first-page":"e93685","DOI":"10.1371\/journal.pone.0093685","article-title":"Induction of gliotoxin secretion in Aspergillus fumigatus by bacteria-associated molecules","volume":"9","author":"Svahn","year":"2014","journal-title":"PLoS ONE"},{"key":"B276","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/md12010069","article-title":"Gliotoxin isolated from marine fungus Aspergillus sp. induces apoptosis of human cervical cancer and chondrosarcoma cells","volume":"12","author":"Nguyen","year":"2013","journal-title":"Mar Drugs"},{"key":"B277","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijporl.2012.12.027","article-title":"Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis","volume":"77","author":"Clamp","year":"2013","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B278","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/lary.23673","article-title":"Current use of intralesional cidofovir for recurrent respiratory papillomatosis","volume":"123","author":"Derkay","year":"2013","journal-title":"Laryngoscope"},{"key":"B279","first-page":"1837","article-title":"Antiviral medication in sexually transmitted diseases","volume":"13","author":"Mlynarczyk-Bonikowska","year":"2013","journal-title":"Chem"},{"key":"B280","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0194599810395353","article-title":"Inhaled cidofovir as an adjuvant therapy for recurrent respiratory papillomatosis","volume":"144","author":"Ksiazek","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B281","doi-asserted-by":"publisher","first-page":"e5018","DOI":"10.1371\/journal.pone.0005018","article-title":"Novel anti-metastatic action of cidofovir mediated by inhibition of E6\/E7, CXCR4 and Rho\/ROCK signaling in HPV tumor cells","volume":"4","author":"Amine","year":"2009","journal-title":"PLoS ONE"},{"key":"B282","volume-title":"A Randomized Double-Blind Placebo-Controlled Trial of AV2-BOBE-1 in the Treatment of Cervical Dysplasia","author":"Martinez","year":"2010"},{"key":"B283","first-page":"825","article-title":"Xinfuning combined with Baofukang suppository for 53 cases with cervical high risk human papillomavirus infection","volume":"17","author":"Song","year":"2011","journal-title":"J Oncol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2334-9-156","article-title":"Interferon for the treatment of genital warts: a systematic review","volume":"9","author":"Yang","year":"2009","journal-title":"BMC Infect Dis"},{"key":"B285","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4155\/tde.12.78","article-title":"Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection","volume":"3","author":"Foldvari","year":"2012","journal-title":"Ther Deliv"},{"key":"B286","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ejpb.2013.01.014","article-title":"In vivo sustained der-mal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application","volume":"84","author":"King","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"B287","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/IGC.0000000000000258","article-title":"Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer","volume":"24","author":"Song","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B288","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2013.11.021","article-title":"Treatment of human papilloma virus infection with interferon alpha and ribavirin in a patient with acquired aplastic anemia","volume":"23","author":"Mosa","year":"2014","journal-title":"Int J Infect Dis"},{"key":"B289","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1086\/653428","article-title":"Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin","volume":"51","author":"Shrestha","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B290","first-page":"675","article-title":"Clinical observation of paiteling on treatment of cervicitis combined with high-risk HPV infection","volume":"23","author":"Guo-Qin","year":"2012","journal-title":"Chin J Woman Child Health Res"},{"key":"B291","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1371\/journal.ppat.0020069","article-title":"Carrageenan is a potent inhibitor of papillomavirus infection","volume":"2","author":"Buck","year":"2006","journal-title":"PLoS Pathog"},{"key":"B292","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ygyno.2016.09.003","article-title":"In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel","volume":"143","author":"Novetsky","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B293","first-page":"171","article-title":"Laboratory study on anti-human papillomavirus activity of Bupleurum chinese","volume":"4","author":"Li","year":"2005","journal-title":"Chin J Dermato Venerol Integ Trad W Med."},{"key":"B294","first-page":"1212","article-title":"Therapeutic efficacy of Youdujing preparation in treating cervical high-risk papilloma virus infection patients","volume":"32","author":"Xiao","year":"2012","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"B295","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/md12042019","article-title":"Potential anti-HPV and related cancer agents from marine resources: an overview","volume":"12","author":"Wang","year":"2014","journal-title":"Mar Drugs"},{"key":"B296","first-page":"113","article-title":"Effects of Pinellia extract fraction on expressions of HPVE6 and P53 genes in cervical cancer cell lines","volume":"27","author":"Li","year":"2012","journal-title":"China J Tradit Chin Med Pharm."},{"key":"B297","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5582\/bst.2017.01056","article-title":"Traditional Chinese medicine for human papillomavirus (HPV) infections: a systematic review","volume":"11","author":"Lin","year":"2017","journal-title":"Biosci Trends"},{"key":"B298","first-page":"9","article-title":"Clinical study of Zibai gel on treatment of cervical high-risk human papillomavirus infection","volume":"19","author":"Ma","year":"2012","journal-title":"Chin J Inform TCM."},{"key":"B299","first-page":"57","article-title":"Effect of Chinese medicine Youdujing for human papilloma virus DNA","volume":"15","author":"Hou","year":"1998","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"B300","first-page":"7","article-title":"Preparation and in vitro pharmacodynamics effect of the Youdujing cream","volume":"24","author":"Feng","year":"2004","journal-title":"Chin Hosp Pharm J"},{"key":"B301","first-page":"2036","article-title":"Study of Youdujing in treating HR-HPV infected cervical lesions","volume":"32","author":"Xiao","year":"2011","journal-title":"Guangdong Med J"},{"key":"B302","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3851\/IMP3133","article-title":"Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a phase I study","volume":"22","author":"Squiquera","year":"2017","journal-title":"Antivir Ther"},{"key":"B303","article-title":"Topical composition containing ranpirnase","author":"Sulley","year":"2016"},{"key":"B304","article-title":"Methods of treating human papillomavirus","author":"Saxena","year":"2014"},{"key":"B305","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1124\/mol.105.014191","article-title":"RNA interference against human papilloma virus oncogenes in cervical cancer cells results in increased sensitivity to cisplastin","volume":"68","author":"Putral","year":"2005","journal-title":"Mol Pharmacol"},{"key":"B306","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/1874357901206010204","article-title":"RNA interference for the treatment of papillomavirus disease","volume":"6","author":"Singhania","year":"2012","journal-title":"Open Virol J"},{"key":"B307","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10495-007-0163-8","article-title":"RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53","volume":"13","author":"Sima","year":"2008","journal-title":"Apoptosis"},{"key":"B308","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/sj.cgt.7701118","article-title":"New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer","volume":"15","author":"Yamato","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"B309","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ygyno.2011.10.028","article-title":"Transcriptional gene silencing of HPV16 E6\/E7 induces growth inhibition via apoptosis in vitro and in vivo","volume":"124","author":"Zhou","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B310","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/cgt.2010.38","article-title":"Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers","volume":"17","author":"Chang","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"B311","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/icb.2011.19","article-title":"siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo","volume":"90","author":"Khairuddin","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1525-1438.2006.00384.x","article-title":"Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo","volume":"16","author":"Niu","year":"2006","journal-title":"Int J Gynecol. Cancer."},{"key":"B313","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/jcm4051126","article-title":"Human papillomavirus: current and future RNAi therapeutic strategies for cervical cancer","volume":"4","author":"Jung","year":"2015","journal-title":"J Clin Med"},{"key":"B314","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-based therapeutics: current progress and future prospects","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem Biol"},{"key":"B315","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1358\/dnp.2008.21.3.1203412","article-title":"Toll-like receptor 7 agonists and skin","volume":"21","author":"Novak","year":"2008","journal-title":"Drug News Perspect"},{"key":"B316","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3851\/IMP2612","article-title":"Targeting human papilloma virus genome replication for antiviral drug discovery","volume":"18","author":"Archambault","year":"2013","journal-title":"Antivir Ther"},{"key":"B317","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1002\/ijc.25302","article-title":"Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia","volume":"127","author":"Terlou","year":"2010","journal-title":"Int J Cancer"},{"key":"B318","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/11209370-000000000-00000","article-title":"Polyphenon E 10% ointment: in immunocompetent adults with external genital and perianal warts","volume":"13","author":"Hoy","year":"2012","journal-title":"Am J Clin Dermatol."},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089350","article-title":"PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer","author":"Guo","year":"2014","journal-title":"PLoS ONE"},{"key":"B320","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5114\/wo.2018.73892","article-title":"Versatile CAR T-cells for cancer immunotherapy","volume":"22","author":"Chu","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"B321","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","article-title":"Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients","volume":"67","author":"Ben-Avi","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B322","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1746-1596-9-101","article-title":"Characterization of two new monoclonal antibodies agaisnst human papillomavirus type 16 L1 protein","volume":"1","author":"Wang","year":"2014","journal-title":"Diag Pathol."},{"key":"B323","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4049\/jimmunol.196.Supp.214.19","article-title":"Serial monoclonal antibody administration demonstrates theraprutic effects via induction of apoptosis in HPV related cervical cancer","volume":"196","author":"Bhadauria","year":"2016","journal-title":"J Immunol"},{"key":"B324","first-page":"31","article-title":"Advances in diagnosis and treatment of HPV ocular surface infections","volume":"4","author":"Kalogeropoulos","year":"2015","journal-title":"Med Hypothesis Discov Innov. Opthalmol"},{"key":"B325","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3928\/0191-3913-19831101-01","article-title":"Dinitrochlorobenzene and debulking therapy of conjunctival papilloma","volume":"20","author":"Burns","year":"1983","journal-title":"J Pedriatr Ophthalmol Strabismus"},{"key":"B326","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.survophthal.2003.10.008","article-title":"Tumors of the conjunctiva and cornea","volume":"49","author":"Shields","year":"2004","journal-title":"Surv. Ophthalmol"},{"key":"B327","doi-asserted-by":"publisher","first-page":"e1091","DOI":"10.1038\/cddis.2014.62","article-title":"Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy","volume":"5","author":"Pogorzelski","year":"2014","journal-title":"Cell Death Dis"},{"key":"B328","article-title":"Compounds for the treatment of cancers associated with human papillomavirus","author":"Piramal","year":"2012","journal-title":"WO"},{"key":"B329","article-title":"Compounds for the treatment of HPV-induced carcinoma.WO 2016027005 A1","author":"Rajendran","year":"2016"},{"key":"B330","article-title":"Human papillomavirus E7 antigen compositions and uses thereof","author":"Webb","year":"2013"},{"key":"B331","article-title":"Method of vaccination against human papilloma virus","author":"Colau","year":"2013"},{"key":"B332","article-title":"Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof","author":"Preville","year":"2014"},{"key":"B333","article-title":"Human papilloma virus treatment","author":"Neefe","year":"2008"},{"key":"B334","article-title":"Methods of treatment of hpv related diseases","author":"Wu","year":"2015"},{"key":"B335","article-title":"Compositions and methods for cell targeted hpv treatment","author":"Quake","year":"2016"},{"key":"B336","volume-title":"Use of New Type of anti-HPVpharmaceutical Preparation","author":"Liu","year":"2016"},{"key":"B337","article-title":"Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection","author":"Roden","year":"2010"},{"key":"B338","article-title":"Compound podophyllotoxin gel for treating HPV virus and preparation method thereof","author":"Lide","year":"2016"},{"key":"B339","article-title":"Pharmaceutical composition using stryphnodendron extracts for treating HPV infections","author":"Neto","year":"2015"},{"key":"B340","article-title":"Abd-Elazem IS","author":"Huang","year":"2015"},{"key":"B341","article-title":"Vaginal cream for the treatment of papilloma infection comprising docosanol, turmeric, amla and aloe","author":"Bertin","year":"2013"},{"key":"B342","article-title":"Treatment of cancer and benign proliferative disorders","author":"Hampson","year":"2015"},{"key":"B343","article-title":"Recombinant human papillomavirus type 18 vaccine","author":"Joyce","year":"1998"},{"key":"B344","article-title":"Composition for treatment and preventative of the human papilloma virus HPV infection, ulcerations and boils","author":"Alessa","year":"2016"},{"key":"B345","article-title":"Methods and materials for treating human papillomavirus infections","author":"Clawson","year":"2010"},{"key":"B346","article-title":"Topical treatment and prevention of human papilloma virus (HPV) infection","author":"Buyuktimkin","year":"2005"},{"key":"B347","article-title":"Guanidinyl-substituted polyamides useful for treating human papilloma virus","author":"Bashkin","year":"2015"},{"key":"B348","article-title":"Genes encoding major capsid protein L1 of human papilloma virus","author":"Zhang","year":"2009"},{"key":"B349","article-title":"Vaccines for human papilloma virus and methods for using the same","author":"Weiner","year":"2015"},{"key":"B350","volume-title":"Human Papilloma Virus Vectors","author":"Apt","year":"2002"},{"key":"B351","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/php.12769","article-title":"Effectiveness of photodynamic therapy in elimination of HPV-16 and HPV-18 associated with CIN I in Mexican women","volume":"93","author":"Maldonado","year":"2017","journal-title":"Photochem Photobiol"},{"key":"B352","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pdpdt.2017.11.005","article-title":"Dynamics of HPV viral loads reflect the treatment effect of photodynamic therapy in genital warts","volume":"21","author":"Hu","year":"2018","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B353","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/lsm.20686","article-title":"Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate","volume":"40","author":"Soergel","year":"2008","journal-title":"Lasers Surg Med."},{"key":"B354","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijgo.2009.09.012","article-title":"Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions","volume":"108","author":"Chumworathayi","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"B355","doi-asserted-by":"publisher","first-page":"e111037","DOI":"10.1371\/journal.pone.0111037","article-title":"Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2\/3 in HIV-positive women in Kenya","volume":"9","author":"De Vuyst","year":"2014","journal-title":"PLoS ONE"},{"key":"B356","doi-asserted-by":"publisher","first-page":"46","DOI":"10.22038\/IJN.2011.5155","article-title":"Treatment of a giant genital wart in an infant via cryotherapy: report of case","volume":"2","author":"Farhat","year":"2011","journal-title":"Iranian J Neonatol"},{"key":"B357","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1086\/598981","article-title":"Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections","volume":"199","author":"Castle","year":"2009","journal-title":"J Infect Dis"},{"key":"B358","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5468\/ogs.2017.60.2.200","article-title":"Efficacy of loop electrosurgical excision procedure with cold coagulation for treating cervical intraepithelial neoplasia: a two center cohort study","volume":"60","author":"Kim","year":"2017","journal-title":"Obstet Gynecol Sci"},{"key":"B359","doi-asserted-by":"publisher","first-page":"S849","DOI":"10.1093\/cid\/civ813","article-title":"Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines","volume":"61","author":"Park","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B360","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000292283","article-title":"Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection","volume":"41","author":"Davila","year":"1996","journal-title":"Gynecol Obstet Invest"},{"key":"B361","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3892\/or.10.5.1437","article-title":"Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions","volume":"10","author":"Niwa","year":"2003","journal-title":"Oncol Rep"},{"key":"B362","doi-asserted-by":"publisher","first-page":"314.e1","DOI":"10.1016\/j.ajog.2013.12.042","article-title":"Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial","volume":"210","author":"Rahangdale","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"B363","doi-asserted-by":"publisher","first-page":"E1081","DOI":"10.3390\/ijms19041081","article-title":"Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study","volume":"19","author":"Akhtar","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B364","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s11671-016-1307-y","article-title":"Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal Nanotechnology","volume":"11","author":"Wang","year":"2016","journal-title":"Nanoscale Res Lett"},{"key":"B365","first-page":"7364","article-title":"Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand","volume":"62","author":"Koivusalo","year":"2002","journal-title":"Cancer Res"},{"key":"B366","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.tjog.2012.09.006","article-title":"Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical\/vaginal intraepithelial neoplasia","volume":"51","author":"Lin","year":"2012","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B367","first-page":"93","article-title":"Cidofovir in the treatment of HPV-associated lesions","volume":"63","author":"Snoeck","year":"2001","journal-title":"Verh K Acad Geneeskd Belg"},{"key":"B368","doi-asserted-by":"publisher","first-page":"47302","DOI":"10.18632\/oncotarget.10100","article-title":"Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms","volume":"7","author":"Mertens","year":"2016","journal-title":"Oncotarget"},{"key":"B369","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00405-014-3055-x","article-title":"Use of cidofovir in HPV patients with recurrent respiratory papillomatosis","volume":"271","author":"Grasso","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B370","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1590\/S1413-86702007000300017","article-title":"Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin","volume":"11","author":"Pavan","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"B371","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1650841","article-title":"Herpes simplex virus and human papillomavirus coinfections in hyperimmunoglobulin E syndrome presenting as a conjunctival mass lesion","author":"Akbari","year":"2017","journal-title":"Case Rep Med"},{"key":"B372","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/10430340360464705","volume":"14","author":"Sethi","year":"2003","journal-title":"Hum Gene Ther"},{"key":"B373","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3923\/jbs.2014.381.386","article-title":"Miraculous effect of smoke of pine tree fruit on human wart treatment: a case series","volume":"14","author":"Doudi","year":"2014","journal-title":"J Biol Sci"},{"key":"B374","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3892\/mco.2017.1454","article-title":"Effect of paiteling on human papillomavirus infection of the cervix","volume":"7","author":"Tao","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B375","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.04.012","article-title":"Study Group","author":"Magnan","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B376","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/095646249500600407","article-title":"Self-treatment of female external genital warts with 0","volume":"6","author":"Hellberg","year":"1995","journal-title":"Int J STD AIDS"},{"key":"B377","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.3892\/ol.2017.6091","article-title":"Synergistic cytotoxic effects of a combined treatment of a Pinellia pedatisecta lipid-soluble extract and cisplatin on human cervical carcinoma in vivo","volume":"13","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"key":"B378","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1933719106298189","article-title":"Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells","volume":"14","author":"Lea","year":"2007","journal-title":"Reprod Sci"},{"key":"B379","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3892\/mmr.2012.1246","article-title":"Induction of apoptosis by chitosan\/HPV16 E7 siRNA complexes in cervical cancer cells","volume":"7","author":"Yang","year":"2013","journal-title":"Mol Med Rep"},{"key":"B380","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0022-5347(05)67254-0","article-title":"Oral cimetidine for the management of genital and perigenital warts in children","volume":"164","author":"Franco","year":"2000","journal-title":"J Urol"},{"key":"B381","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1365-4362.1991.tb02624.x","article-title":"Verrucae treated by levamisole","volume":"30","author":"Amer","year":"1991","journal-title":"Int J Dermatol"},{"key":"B382","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1590\/S0365-05962012000400011","article-title":"Treatment of common warts with the immune stimulant Propionium bacterium parvum","volume":"87","author":"Nasser","year":"2012","journal-title":"An Bras Dermatol"},{"key":"B383","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1468-3083.2009.03169.x","article-title":"Oral zinc sulphate in recalcitrant multiple viral warts: a pilot study","volume":"23","author":"Sadighha","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B384","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.urology.2004.09.025","article-title":"Application of viable bacille Calmette-Gu\u00e9rin topically as a potential therapeutic modality in Condylomata acuminata: a placebo-controlled study","volume":"65","author":"Metawea","year":"2005","journal-title":"Urology"},{"key":"B385","doi-asserted-by":"publisher","first-page":"383","DOI":"10.12891\/ceog4112.2018","article-title":"Cantharidin is superior to trichloroacetic acid for the treatment of non-mucosal genital warts: a pilot randomized controlled trial","volume":"45","author":"Recanati","year":"2018","journal-title":"Clin Exp Obstet Gynecol"},{"key":"B386","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-4362.2001.01242.x","article-title":"Topical formic acid puncture technique for the treatment of common warts","volume":"40","author":"Bhat","year":"2001","journal-title":"Int J Dermatol"},{"key":"B387","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0190-9622(83)70112-X","article-title":"Bleomycin in the treatment of recalcitrant warts","volume":"9","author":"Shumer","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"B388","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"B389","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","article-title":"Development of a highly thermostable, adjuvanted human papillomavirus vaccine","volume":"94","author":"Hassett","year":"2015","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:33:37Z","timestamp":1694028817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":389,"alternative-id":["10.3389\/fimmu.2018.02478"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02478","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"article-number":"2478"}}